<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202955</url>
  </required_header>
  <id_info>
    <org_study_id>808250</org_study_id>
    <nct_id>NCT01202955</nct_id>
  </id_info>
  <brief_title>Pilot Study of Tolcapone in Smokers</brief_title>
  <official_title>Pilot Study of Tolcapone Effects on Abstinence-Induced Cognitive Symptoms in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this within-subject pilot study are: (1) assess the feasibility and safety of
      administering the Catechol-O-Methyl-Transferase (COMT) inhibitor, tolcapone, to smokers, and
      (2) explore whether tolcapone may reduce abstinence-induced cognitive and affective symptoms
      that promote relapse. A secondary exploratory goal is to assess whether these effects may be
      more pronounced in smokers who carry a high risk COMT genotype for smoking relapse: COMT
      val/val.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite decades of research to develop pharmacotherapies for nicotine dependence (ND), with
      current FDA approved medications (bupropion, varenicline and NRTs) the majority (&gt;60%) of
      smokers relapse in the first year following treatment (Lerman, Patterson et al. 2005;
      Tonstad, Tonnesen et al. 2006). Testing novel medications that may reduce abstinence symptoms
      that prompt smoking relapse is a plausible route to identifying new treatments for nicotine
      dependence. The goals of this within-subject pilot study are: (1) assess the feasibility and
      safety of administering the Catechol-O-Methyl-Transferase (COMT) inhibitor, tolcapone, to
      smokers, and (2) explore whether tolcapone may reduce abstinence-induced cognitive and
      affective symptoms that promote relapse. A secondary exploratory goal is to assess whether
      these effects may be more pronounced in smokers who carry a high risk COMT genotype for
      smoking relapse: COMT val/val. Sixteen smokers (8 met/met genotype and 8 val/val genotype)
      who meet study eligibility criteria will complete two 10-day medication periods: one while
      taking tolcapone and one while taking placebo (order counterbalanced). The testing session
      will occur on day 7 of each medication phase and include three computerized tasks.
      Participants will be asked to refrain from smoking for at least 14 hours (overnight) prior to
      the testing day in each medication phase. There will be a 3-day medication taper on days 8-10
      of each medication period, followed by a washout period of at least 7 days between medication
      periods. The main outcomes to be evaluated are participant enrollment and retention, side
      effects, and performance on computerized tasks. Positive results from this pilot study would
      provide a basis for a larger scale investigation to assess the efficacy of tolcapone as a
      medication that ameliorates abstinence induced neurocognitive symptoms in smokers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Eligible Participants Enrolled Who Completed the Study.</measure>
    <time_frame>30 days</time_frame>
    <description>Number of enrolled participants who complete the final study visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>N-back (Working Memory) Correct Reaction Time After Overnight Abstinence.</measure>
    <time_frame>30 days</time_frame>
    <description>To obtain preliminary data on the effects of Tolcapone on abstinence-induced neurocognitive deficits in abstinent smokers with differing COMT genotypes. We examined reaction time differences on the n-back task between tolcapone and placebo treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correct Reaction Time During Attention Task Performance After Overnight Abstinence.</measure>
    <time_frame>30 days</time_frame>
    <description>We wanted to examine the effects of Tolcapone on the Continuous Performance Task (attention task) after overnight abstinence as compared to placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Tolcapone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tolcapone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone</intervention_name>
    <description>Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day</description>
    <arm_group_label>Tolcapone</arm_group_label>
    <other_name>Tasmar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy as determined by a responsible physician, based on a medical evaluation
             including history, physical and psychiatric examination, laboratory tests, liver
             function monitoring.

          2. Smokers who are between 18 and 55 years of age and have an IQ greater than 90.

          3. Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions, listed in the consent form.

          4. Based upon self-report, subjects must smoke &gt;10 cigarettes/day and be interested in
             quitting smoking in the next 6 months (i.e., treatment-seekers).

          5. Women of childbearing potential must consent to using a medically accepted method of
             birth control (e.g., condoms and spermicide, oral contraceptive, Depo-provera
             injection, contraceptive patch, tubal ligation).

        Exclusion Criteria:

        Smoking Behavior

          1. Use of chewing tobacco or snuff

          2. Current enrollment or plans to enroll in another smoking cessation program in the next
             month

          3. Plan to use other nicotine substitutes or smoking cessation treatments in the next
             month

          4. Provide a baseline carbon monoxide (CO) reading &lt; 10ppm

        Alcohol/Drug Exclusion Criteria

          1. History of substance abuse and/or currently receiving treatment for substance abuse
             (e.g., alcohol, opioids, cocaine, marijuana, MDMA/ecstasy, or stimulants)

          2. Current alcohol consumption that exceeds &gt;14 standard drinks/week for men and &gt;7
             standard drinks/week for women over the last 6 months

        Medication Exclusion Criteria

          1. Current use or recent discontinuation (within last 4-weeks) of any medication
             including the following:

               -  Any form of psychotropic medications including:

                    -  antipsychotics,

                    -  atypical antipsychotics,

                    -  mood-stabilizers,

                    -  anti-depressants (tricyclics, SSRI's, MAOI's, nonselective MAOIs,
                       Wellbutrin/Zyban),

                    -  anti-panic agents,

                    -  anti-obsessive agents,

                    -  anti-anxiety agents, and

                    -  stimulants (e.g., Provigil, Ritalin)

                    -  Varenicline

               -  Medication for chronic pain

               -  Anti-coagulants (e.g., Warfarin)

               -  Any heart medications

               -  Daily medication for asthma

               -  Apomorphine, dobutamine, isoproterenol, levodopa, methyldopa, or sympathomimetic
                  (e.g., albuterol, pseudoephedrine)

          2. Current use of any smoking cessation medication.

        Medical Exclusion Criteria

          1. Women who are pregnant, planning a pregnancy, or lactating.

          2. History or current diagnosis of psychosis, major depression or bipolar disorder,
             schizophrenia, or any Axis 1 disorder as identified by the MINI.

          3. Serious or unstable disease within the past 6 months (e.g., cancer [except squamous
             cell carcinoma], heart disease, HIV, liver disease, Parkinson's disease).

          4. History of epilepsy or a seizure disorder.

          5. History or current diagnosis (last 6-months) of abnormal rhythms and/or tachycardia
             (&gt;100 beats/minute); history or current diagnosis of chronic obstructive pulmonary
             disease (COPD), cardiovascular disease (stroke, angina, coronary heart disease), heart
             attack in the last 6 months, uncontrolled hypertension (SBP&gt;150 or DBP&gt;90)

          6. History of Kidney and/or liver failure (including transplant) or problems (e.g.,
             cirrhosis); current liver disease or impairment.

          7. History or current diagnosis of hepatitis.

          8. Liver function tests more than 20% outside of the normal range.

          9. Allergies to the study medication, tolcapone (Tasmar).

         10. History of severe, uncontrolled muscle movements (e.g., uncontrolled jerking,
             twitching) or a certain severe muscle problem (rhabdomyolysis).

         11. Experience of dizziness or lightheadedness upon standing on a regular basis (i.e.,
             daily).

        Genetic Profile

          1. Individuals with the heterozygous genotype (val/met) on the catechol-methyl
             transferase (COMT) gene. (Note: this is a small pilot study comparing effects of
             Tolcapone on cognitive performance between val/val (n=8) individuals.) Future research
             done at our center will plan to include those carrying the val/met genotype.

          2. Individuals with the homozygous genotype, met/met, on the COMT gene. As of December
             2008, the study has accrued 8 met/met participants. To balance the genotype groups,
             the study will recruit an equal number of participants with the val/val genotype on
             the COMT gene and not include any further participants with the homozygous, met/met
             genotype. Future research done at our center will plan to include those carrying the
             met/met genotype.

          3. Non-European ancestry as determined by self report at initial telephone screening; we
             expect there to be ethnic differences in allele frequencies for COMT; therefore, as of
             December 2008, to reduce ethnic admixture that could bias the genetic analysis of this
             small sample, the study will be restricted to individuals of European ancestry. All
             participants of non-European ancestry will be referred to other studies at our center.

        General Exclusion

          1. Any medical condition or concomitant medication that could compromise participant
             safety or treatment, as determined by the Principal Investigator and/or Study
             Physician.

          2. Inability to provide informed consent or complete any of the study tasks as determined
             by the Principal Investigator and/or Study Physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caryn Lerman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>October 6, 2010</results_first_submitted>
  <results_first_submitted_qc>March 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2011</results_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Caryn Lerman/Center Director</name_title>
    <organization>University of Pennsylvania</organization>
  </responsible_party>
  <keyword>Smoking, Abstinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited using mass media advertising from July 2008 to April 2009.</recruitment_details>
      <pre_assignment_details>Each participant's catechol-o-methyl transferase (COMT) genotype was determined prior to medication assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tolcapone First, Then Placebo</title>
          <description>Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Tolcapone</title>
          <description>Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: 10 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: 7 Days (Wash-Out)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3: 10 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tolcapone First, Then Placebo</title>
          <description>Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Tolcapone</title>
          <description>Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.55" spread="11.41"/>
                    <measurement group_id="B2" value="40.5" spread="11.77"/>
                    <measurement group_id="B3" value="38.63" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Eligible Participants Enrolled Who Completed the Study.</title>
        <description>Number of enrolled participants who complete the final study visit</description>
        <time_frame>30 days</time_frame>
        <population>Number of Participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolcapone First, Then Placebo</title>
            <description>Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Tolcapone</title>
            <description>Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eligible Participants Enrolled Who Completed the Study.</title>
          <description>Number of enrolled participants who complete the final study visit</description>
          <population>Number of Participants who completed the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N-back (Working Memory) Correct Reaction Time After Overnight Abstinence.</title>
        <description>To obtain preliminary data on the effects of Tolcapone on abstinence-induced neurocognitive deficits in abstinent smokers with differing COMT genotypes. We examined reaction time differences on the n-back task between tolcapone and placebo treatment.</description>
        <time_frame>30 days</time_frame>
        <population>Only participants who completed both sessions were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Tolcapone First, Then Placebo</title>
            <description>Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Tolcapone</title>
            <description>Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally</description>
          </group>
        </group_list>
        <measure>
          <title>N-back (Working Memory) Correct Reaction Time After Overnight Abstinence.</title>
          <description>To obtain preliminary data on the effects of Tolcapone on abstinence-induced neurocognitive deficits in abstinent smokers with differing COMT genotypes. We examined reaction time differences on the n-back task between tolcapone and placebo treatment.</description>
          <population>Only participants who completed both sessions were analysed</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="597.09" spread="136.85"/>
                    <measurement group_id="O2" value="608.21" spread="151.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correct Reaction Time During Attention Task Performance After Overnight Abstinence.</title>
        <description>We wanted to examine the effects of Tolcapone on the Continuous Performance Task (attention task) after overnight abstinence as compared to placebo.</description>
        <time_frame>30 days</time_frame>
        <population>Only participants who completed both study phases were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolcapone First, Then Placebo</title>
            <description>Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Tolcapone</title>
            <description>Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Correct Reaction Time During Attention Task Performance After Overnight Abstinence.</title>
          <description>We wanted to examine the effects of Tolcapone on the Continuous Performance Task (attention task) after overnight abstinence as compared to placebo.</description>
          <population>Only participants who completed both study phases were analyzed.</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460.14" spread="34.53"/>
                    <measurement group_id="O2" value="457.64" spread="39.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>No adverse events, serious or other, were reported during by any participants during this pilot study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tolcapone First, Then Placebo</title>
          <description>To maintain the study blind, both the active Tolcapone and placebo medication periods used an increased-titration dose. Below is the breakdown of the increase in dosing of the active Tolcapone:
Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally
During the placebo period, all participants followed the above dosing schedule; however, the capsules contained no tolcapone.</description>
        </group>
        <group group_id="E2">
          <title>Placebo First, Then Tolcapone</title>
          <description>To maintain the study blind, both the active Tolcapone and placebo medication periods used an increased-titration dose. Below is the breakdown of the increase in dosing of the active Tolcapone:
Day 1: 100mg three times per day orally Day 2 – Day 7: 200mg three times per day orally Day 8: 200mg twice a day orally Day 9: 200mg once a day orally Day 10: 100mg once a day orally
During the placebo period, all participants followed the above dosing schedule; however, the capsules contained no tolcapone.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Caryn Lerman</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-7141</phone>
      <email>clerman@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

